-- Jadestone Energy周一宣布,已签署一项针对其越南气田的天然气销售协议,目标日产量为8000万标准立方英尺,预计将于2028年底投产。 该公司表示,该协议涵盖来自越南西南部近海Nam Du和U Minh气田的天然气供应。 该公司补充说,该协议符合2026年3月18日批准的开发计划,目标是在2028年底实现首次投产。 Jadestone表示,根据协议,天然气将按照既定的供应和定价条款出售给越南国家石油公司(Petrovietnam)旗下的PV Gas公司。 该公司补充说,合同规定日供应量为8000万标准立方英尺,并具有高达110%的灵活性,以及涵盖90%供应量的照付不议条款。 Jadestone表示,定价与越南历史天然气进口水平挂钩,协议中包含年度价格递增条款,以确保长期收入的可预测性。 该公司指出,这些油田拥有约3200万桶油当量探明和概算储量,具备长期生产潜力。 Jadestone公司还表示,附近油田也蕴藏着巨大的增值潜力,预计可额外提供高达1.5万亿立方英尺的天然气,这有望延长产量稳定期并提升项目价值。 首席执行官T. Mitch Little表示,该协议是Jadestone公司发展历程中的一个重要里程碑,有助于推进项目执行,重点在于合同授予,同时支持越南的能源安全、经济增长和长期减排目标。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.